Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the recurrence
PAM50 HER2-enriched subtype enriches for tumor response to neoadjuvant anthracyclines/Taxane and Trastuzumab/Taxane containing regimens in HER2-positive breast cancer (Abstract S5-2, Cheang M et al.)
